Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
To date, the impact of background glucocorticoids (GC) on the efficacy and safety of abatacept or adalimumab in patients with active rheumatoid arthritis (RA) is not clearly established. This post hoc analysis of (AMPLE) trial (NCT00929864) compared efficacy and safety outcomes over 2 years in patie...
Main Authors: | Yannick Degboé, Michael Schiff, Michael Weinblatt, Roy Fleischmann, Harris A. Ahmad, Arnaud Constantin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/6/2017 |
Similar Items
-
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
by: Roy Fleischmann, et al.
Published: (2019-10-01) -
Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study
by: Ernest Choy, et al.
Published: (2021-02-01) -
Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01) -
Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+
by: Leslie R. Harrold, et al.
Published: (2023-02-01) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)